Remepy has raised US$36m to advance its Parkinson’s treatment into Phase III trials and extend its model of pairing medicines with therapeutic software.
The Series A round, co-led by Merck KGaA’s M Ventures and O.G. Venture Partners, brings the startup’s total funding to US$62m.
Existing and new backers include NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital and IT-Farm Corp.
Co-chief executives Michal Tsur and Or Shoval believe medicine is “entering a new era, where every breakthrough drug will be paired with personalised intelligence to maximise its impact for every patient.”
Working alongside pharmaceutical companies, Remepy is developing treatments that combine prescription medicines with AI-powered therapeutic apps.
The platform combines pharmacology with adaptive physical, cognitive and behavioural interventions, using real-time data to tailor treatment to each patient’s needs and profile.
Earlier this year, the startup partnered with investor Merck KGaA to investigate the potential of hybrid drugs across a range of disease areas, initially focusing on rare tumours.
It is also exploring how the combined therapies could address pre-term birth by modulating the immune response and reducing stress.
The company’s lead Parkinson’s programme pairs levodopa with a digital protocol covering motor skills, speech therapy, cognition, sleep, stress reduction, attention training and psychoeducation.
Phase IIa results showed significant improvements in motor and non-motor symptoms, alongside functional MRI evidence of strengthened connectivity in motor and limbic brain circuits linked to improvements in motor control and mood.
The company is now preparing for global Phase III development, which is expected to begin later this year.
Remepy’s model is also gaining interest among doctors.
A recent FirstWord snap poll of nearly 230 physicians in the US and Europe found that nearly half would be more likely to prescribe a drug if it were paired with a digital therapeutic.
Nineteen per cent said the combination would make them more likely to choose it over a comparable drug-only treatment.
